Moderna's mRNA-1273 Vaccine Formulation

The mRNA-1273 vaccine candidate, manufactured by Moderna, encodes the S-2P antigen, consisting of the SARS-CoV-2 glycoprotein with a transmembrane anchor and an intact S1–S2 cleavage site. S-2P is stabilized in its prefusion conformation by two consecutive proline substitutions at amino acid positions 986 and 987, at the top of the central helix in the S2 subunit.^{8 (link)} The lipid nanoparticle capsule composed of four lipids was formulated in a fixed ratio of mRNA and lipid. The mRNA-1273 vaccine was provided as a sterile liquid for injection at a concentration of 0.5 mg per milliliter. Normal saline was used as a diluent to prepare the doses administered.

Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link: Access Free Full Text.

Jackson L.A., Anderson E.J., Rouphael N.G., Roberts P.C., Makhene M., Coler R.N., McCullough M.P., Chappell J.D., Denison M.R., Stevens L.J., Pruijssers A.J., McDermott A., Flach B., Doria-Rose N.A., Corbett K.S., Morabito K.M., O’Dell S., Schmidt S.D., Swanson PA I.I., Padilla M., Mascola J.R., Neuzil K.M., Bennett H., Sun W., Peters E., Makowski M., Albert J., Cross K., Buchanan W., Pikaart-Tautges R., Ledgerwood J.E., Graham B.S, & Beigel J.H. (2020). An mRNA Vaccine against SARS-CoV-2 — Preliminary Report. The New England Journal of Medicine.

Publication 2020

Amino acid substitutions Antigen Capsule Cleavage Glycoprotein Helix Lipid Lipid nanoparticle Mrna Mrna vaccine Normal saline Proline Sars cov 2 Sterile Subunit

Corresponding Organization :

Other organizations : National Institute of Allergy and Infectious Diseases, Kaiser Permanente, Children's Healthcare of Atlanta, University of Maryland, Baltimore, Emory University

Top 5 similar protocols

Protocol cited in 7 other protocols

Variable analysis

independent variables

Formulation of the lipid nanoparticle capsule composed of four lipids in a fixed ratio of mRNA and lipid

dependent variables

Immune response to the mRNA-1273 vaccine candidate

control variables

Concentration of the mRNA-1273 vaccine at 0.5 mg per milliliter
Use of normal saline as a diluent to prepare the doses administered

controls

Positive control: Not specified
Negative control: Not specified

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!